{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:51Z","timestamp":1789753431799,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004001","name":"Science and Technology Foundation of Guizhou Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Bureau and Affiliated Hospital of Zunyi Medical College","award":["(2016)7485"],"award-info":[{"award-number":["(2016)7485"]}]},{"name":"Zunyi Medical College","award":["(2017) 5733-034"],"award-info":[{"award-number":["(2017) 5733-034"]}]},{"name":"Special Funds for Science and Technology Research of Traditional Chinese and National Medicine in Guizhou","award":["QZYY 2017-084"],"award-info":[{"award-number":["QZYY 2017-084"]}]},{"name":"High-level Innovative Talent Program in Guizhou","award":["fzc 120171001"],"award-info":[{"award-number":["fzc 120171001"]}]},{"name":"Doctoral Fund of Zunyi Medical College","award":["F-617"],"award-info":[{"award-number":["F-617"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.intimp.2019.105747","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T05:47:09Z","timestamp":1563428829000},"page":"105747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines"],"prefix":"10.1016","volume":"75","author":[{"given":"Fen-Lian","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Li","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Sheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Tao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.105747_bb0005","first-page":"115","article-title":"Cancer statistics in China","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2019.105747_bb0010","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2019.105747_bb0015","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2019.105747_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.intimp.2019.105747_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/thorax.57.1.20","article-title":"Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review","volume":"57","author":"Clegg","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.intimp.2019.105747_bb0030","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Masters","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/thoraxjnl-2014-205914","article-title":"A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer","volume":"70","author":"Pilkington","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.intimp.2019.105747_bb0040","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0045","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/annonc\/mdf063","article-title":"Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival","volume":"13","author":"Conroy","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.1987.5.2.318","article-title":"Cisplatin-induced hepatic toxicity","volume":"5","author":"Pollera","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2018.03.009","article-title":"Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies","volume":"827","author":"Shahid","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105747_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.heares.2013.02.002","article-title":"Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity","volume":"299","author":"Waissbluth","year":"2013","journal-title":"Hear. Res."},{"key":"10.1016\/j.intimp.2019.105747_bb0065","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/imt.15.62","article-title":"An immunological view of chemotherapy","volume":"7","author":"Tsung","year":"2015","journal-title":"Immunotherapy"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2019.105747_bb0070","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/0169-5002(94)91691-8","article-title":"Toxicity of combined radiation and chemotherapy in non-small cell lung cancer","volume":"10","author":"Van Houtte","year":"1994","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2019.105747_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0169-5002(01)00334-8","article-title":"Lung toxicity following chest irradiation in patients with lung cancer","volume":"35","author":"Abratt","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2019.105747_bb0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cllc.2013.03.002","article-title":"Toxicity of concurrent radiochemotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature","volume":"14","author":"Koning","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.intimp.2019.105747_bb0085","first-page":"1","article-title":"Immunotherapy for lung cancer: advances and prospects","volume":"5","author":"Yang","year":"2016","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2019.105747_bb0090","article-title":"Thymic peptides for treatment of cancer patients","volume":"16","author":"Wolf","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2019.105747_bb0095","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2019.105747_bb0100","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.451537","article-title":"A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin","volume":"204","author":"Goldstein","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.intimp.2019.105747_bb0105","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1515\/bchm2.1983.364.2.933","article-title":"Immuno-regulating peptides, I. synthesis and structure-activity relationships of thymopentin analogs","volume":"364","author":"Kisfaludy","year":"1983","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"10.1016\/j.intimp.2019.105747_bb0110","first-page":"470+1","article-title":"Combination of thymosin-\u03b11 with low-dose gemcitabine for advanced non-small cell lung cancer in elderly patients","volume":"25","author":"Liang","year":"2010","journal-title":"J Pract Oncol"},{"key":"10.1016\/j.intimp.2019.105747_bb0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/TA.0000000000000909","article-title":"Ulinastatin and\/or thymosin alpha1 for severe sepsis: a systematic review and meta-analysis","volume":"80","author":"Feng","year":"2016","journal-title":"J. Trauma Acute Care Surg."},{"key":"10.1016\/j.intimp.2019.105747_bb0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jcrc.2016.12.013","article-title":"Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients","volume":"39","author":"Liu","year":"2017","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.intimp.2019.105747_bb0125","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12879-016-1823-5","article-title":"The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Infect. Dis."},{"issue":"2011","key":"10.1016\/j.intimp.2019.105747_bb0130","first-page":"29","article-title":"Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis","volume":"19","author":"Mao","year":"2011","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.intimp.2019.105747_bb0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.antiviral.2007.10.014","article-title":"Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis","volume":"77","author":"Yang","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.intimp.2019.105747_bb0140","first-page":"1776","article-title":"Effect of thymosin \u03b11 on apoptosis of lung cancer cell A549","author":"Liu","year":"2016","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.intimp.2019.105747_bb0145","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10495-015-1151-z","article-title":"A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects","volume":"20","author":"Lao","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2019.105747_bb0150","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10495-015-1138-9","article-title":"Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K\/Akt\/mTOR signaling pathway","volume":"20","author":"Guo","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2019.105747_bb0155","first-page":"5214","article-title":"Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo","volume":"53","author":"Moody","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2019.105747_bb0160","first-page":"3571","article-title":"High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma","volume":"18","author":"Pica","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2019.105747_bb0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0304-3835(00)00405-5","article-title":"Thymosin alpha1 is chemopreventive for lung adenoma formation in A\/J mice","volume":"155","author":"Moody","year":"2000","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2019.105747_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1196\/annals.1415.040","article-title":"Thymosin alpha1 as a chemopreventive agent in lung and breast cancer","volume":"1112","author":"Moody","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2019.105747_bb0175","first-page":"99","article-title":"Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy","volume":"7","author":"Bedikian","year":"1987","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0180","first-page":"27","article-title":"Synergistic and protective effect of thymalfasin in treatment of NSCLC: a meta-analysis","volume":"26","author":"Lin","year":"2016","journal-title":"Pharm Today"},{"key":"10.1016\/j.intimp.2019.105747_bb0185","first-page":"75","article-title":"Evaluation of thymopentin in adjuvant therapy for patients with lung cancer: a meta-analysis of randomized trials","volume":"4","author":"Li","year":"2015","journal-title":"J Integr Technol"},{"key":"10.1016\/j.intimp.2019.105747_bb0190","first-page":"107","article-title":"Clinical study of thymosin \u03b11 combined with pemetrexed in the treatment of elderly patients with advanced lung adenocarcinoma","volume":"30","author":"Mao","year":"2017","journal-title":"J Basic Clin Oncol"},{"key":"10.1016\/j.intimp.2019.105747_bb0195","first-page":"42","article-title":"Efficacy of thymosin combined with chemotherapy in treatment of patients with non-small cell lung cancer and its influence on immune function","volume":"21","author":"You","year":"2017","journal-title":"J Clin Med Pract"},{"key":"10.1016\/j.intimp.2019.105747_bb0200","first-page":"112","article-title":"Clinical study of thymopentin with TC regimen in the treatment of advanced non-small cell lung cancer","author":"Li","year":"2018","journal-title":"Chin Pract Med"},{"key":"10.1016\/j.intimp.2019.105747_bb0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1759-7714.2011.00057.x","article-title":"Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Jiang","year":"2011","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.intimp.2019.105747_bb0210","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.intimp.2019.105747_bb0215","first-page":"47S","article-title":"Value of the new TNM staging system for lung cancer","volume":"96","author":"Mountain","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2019.105747_bb0220","unstructured":"J.P.T Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, London, 2011. Available at: http:\/\/ wwwhandbookcochraneorg\/."},{"key":"10.1016\/j.intimp.2019.105747_bb0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2019.105747_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.1154","article-title":"Response evaluation criteria in solid tumors (RECIST): new guidelines","volume":"37","author":"Tsuchida","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0235","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2019.105747_bb0240","first-page":"220","article-title":"Karnofsky performance scale","volume":"27","author":"Clancey","year":"1995","journal-title":"J Neurosci Nurs"},{"key":"10.1016\/j.intimp.2019.105747_bb0245","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology","volume":"25","author":"Trotti","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105747_bb0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.intimp.2019.105747_bb0255","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.intimp.2018.06.012","article-title":"Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: a meta-analysis of 16 randomized controlled trials","volume":"61","author":"Xiao","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2019.105747_bb0260","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.intimp.2019.105747_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9081938","article-title":"The antitumor immunity and tumor responses of chemotherapy with or without DC-CIK for non-small-cell lung cancer in China: a meta-analysis of 28 randomized controlled trials","volume":"2018","author":"Xiao","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.intimp.2019.105747_bb0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctim.2018.01.011","article-title":"Can AIDI injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials","volume":"37","author":"Xiao","year":"2018","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.intimp.2019.105747_bb0275","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2019.105747_bb0280","first-page":"309","article-title":"Effect of thymopentin in the prevention of the opportunistic fungal and parasitic infections during treatment of the late cases with lung cancer","volume":"21","author":"Chen","year":"2005","journal-title":"Chin J Zoonoses"},{"key":"10.1016\/j.intimp.2019.105747_bb0285","first-page":"244","article-title":"Effect of thymosin \u03b11 for advanced non-small-cell lung cancer in chemotherapy patients","volume":"15","author":"Wang","year":"2005","journal-title":"Chin Oncol"},{"key":"10.1016\/j.intimp.2019.105747_bb0290","first-page":"77","article-title":"Clinical efficacy of thymosin alpha 1 in the treatment of advanced non-small cell lung cancer","volume":"46","author":"Ma","year":"2006","journal-title":"Shandong Med J"},{"key":"10.1016\/j.intimp.2019.105747_bb0295","first-page":"272","article-title":"Clinical effects of advanced patients with non-small cell lung cancer treatment by thymosin alpha I combined with NP regimens","volume":"5","author":"Hou","year":"2007","journal-title":"J Bethune Mil Med Coll"},{"key":"10.1016\/j.intimp.2019.105747_bb0300","first-page":"764","article-title":"Clinical effects of thymosin alpha 1 combined with chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"15","author":"Shi","year":"2007","journal-title":"PJCCPVD"},{"key":"10.1016\/j.intimp.2019.105747_bb0305","first-page":"289","article-title":"Influence of thymopentin on immunologic function in advanced-stage patients with nonsmall-cell lung cancer","volume":"25","author":"Liu","year":"2008","journal-title":"J Xinxiang Med Univ"},{"key":"10.1016\/j.intimp.2019.105747_bb0310","first-page":"1482","article-title":"Effect of thymosin alpha 1 on T lymphocyte subsets in lung cancer with chemotherapy","volume":"27","author":"Wu","year":"2008","journal-title":"Her Med"},{"key":"10.1016\/j.intimp.2019.105747_bb0315","first-page":"3676","article-title":"Clinical study on the effect and nursing care of bronchogenic carcinoma treated with thymosin alpha1 combined with chemotherapy","volume":"24","author":"Zhen","year":"2008","journal-title":"Modern Med & Health"},{"key":"10.1016\/j.intimp.2019.105747_bb0320","first-page":"2060","article-title":"Clinical effects of thymopentin combined with chemotherapy in the treatment of non-small cell lung cancer","volume":"38","author":"Lin","year":"2009","journal-title":"Chongqing Med J"},{"key":"10.1016\/j.intimp.2019.105747_bb0325","first-page":"83","article-title":"Effect of thymosin alpha 1 on cellular immune function in patients with non-small cell lung cancer during chemotherapy","volume":"49","author":"Sun","year":"2009","journal-title":"Shandong Med J"},{"key":"10.1016\/j.intimp.2019.105747_bb0330","first-page":"146","article-title":"The effect of thymosin alpha 1 on the immune function of patients with advanced lung cancer","volume":"29","author":"Gu","year":"2010","journal-title":"Nei Mongol J TCM"},{"key":"10.1016\/j.intimp.2019.105747_bb0335","first-page":"46","article-title":"Comparative study of thymopentin and megestrol acetate P1 us EP regimen with EP regimen alone in the treatment of advanced non-small cell lung cancer","volume":"5","author":"Zhou","year":"2010","journal-title":"Chin Pract Med"},{"key":"10.1016\/j.intimp.2019.105747_bb0340","first-page":"58+2","article-title":"Clinical effects of thymosin alpha 1 plus NP in the treatment of advanced non-small cell lung cancer","volume":"7","author":"Han","year":"2012","journal-title":"Chin Healthc Innov."},{"key":"10.1016\/j.intimp.2019.105747_bb0345","first-page":"582","article-title":"Clinical efficacy of thymosin alpha 1 in the treatment of middle and advanced non-small cell lung cancer","volume":"23","author":"Li","year":"2012","journal-title":"J Aerosp Med"},{"key":"10.1016\/j.intimp.2019.105747_bb0350","first-page":"493","article-title":"Effect of thymosin alpha 1 on advanced NSCLC immune function and bone marrow suppression","volume":"10","author":"Liu","year":"2012","journal-title":"Clin Educ Gen Pract"},{"issue":"2012","key":"10.1016\/j.intimp.2019.105747_bb0355","first-page":"9","article-title":"The clinical study of NSCLC patients with the maintenance treatment of thymopeptides \u03b11 (T\u03b11) and combined determination of the immune function of the T,B and NK cells","volume":"6","author":"Wang","year":"2012","journal-title":"J Diss Monit & Contr"},{"key":"10.1016\/j.intimp.2019.105747_bb0360","first-page":"261","article-title":"Effects of thymosin \u03b11 on immune function in patients with non-small cell lung cancer treated by chemotherapy","volume":"21","author":"Cai","year":"2014","journal-title":"Chin. J. Clin. Oncol. Rehab."},{"key":"10.1016\/j.intimp.2019.105747_bb0365","first-page":"131","article-title":"Clinical efficacy and cellular immunity of thymosin alpha 1 combined with chemotherapy in the treatment of lung cancer","volume":"8","author":"Shui","year":"2014","journal-title":"Chin. J. Modern Drug Appl."},{"issue":"2014","key":"10.1016\/j.intimp.2019.105747_bb0370","first-page":"683","article-title":"Effect of thymalfasin on the immune function of patients with advanced non-small cell lung cancer","volume":"13","author":"Zhao","year":"2014","journal-title":"Chin. J. Difficult Complicated Cases"},{"key":"10.1016\/j.intimp.2019.105747_bb0375","first-page":"17","article-title":"Thymopentin combined with gemcitabine and carboplatin in the treatment of advanced squamous cell carcinoma of the lung: a clinical study with 56 cases","volume":"15","author":"Chen","year":"2015","journal-title":"World Latest Med. Inform."},{"key":"10.1016\/j.intimp.2019.105747_bb0380","first-page":"199","article-title":"Pharmacoeconomics analysis of Chinese herb injection combined with NP chemotherapy in treatment of non-small cell lung cancer","volume":"21","author":"Wu","year":"2015","journal-title":"Chin. J. Exp. Tradit. Med. Formulae"},{"key":"10.1016\/j.intimp.2019.105747_bb0385","first-page":"41","article-title":"Influence of immune function of thymosin \u03b11 combined with chemotherapy for patients with advanced non-small cell lung cancer","volume":"36","author":"Mo","year":"2015","journal-title":"J. Med. Forum"},{"key":"10.1016\/j.intimp.2019.105747_bb0390","first-page":"9","article-title":"Effect of the combined use of thymopentin and paclitaxel and cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"31","author":"Sha","year":"2015","journal-title":"J. Baotou Med. Coll."},{"key":"10.1016\/j.intimp.2019.105747_bb0395","first-page":"27","article-title":"Synergistic and protective effect of thymalfasin in treatment of NSCLC: a meta-analysis","volume":"26","author":"Lin","year":"2016","journal-title":"Pharm. Today"},{"key":"10.1016\/j.intimp.2019.105747_bb0400","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12072-009-9132-3","article-title":"A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"3","author":"Gish","year":"2009","journal-title":"Hepatol. Int."},{"issue":"1994","key":"10.1016\/j.intimp.2019.105747_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00686277","article-title":"Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review","volume":"35","author":"Pinzani","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105747_bb0410","first-page":"350","article-title":"Chemotherapy-associated hepatotoxicity in colorectal cancer","volume":"19","author":"Cai","year":"2014","journal-title":"J. BUON"},{"key":"10.1016\/j.intimp.2019.105747_bb0415","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919310082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919310082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:44:35Z","timestamp":1762551875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919310082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":83,"alternative-id":["S1567576919310082"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105747","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105747"}}